jueves, 1 de octubre de 2026

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

News articleYahoo Finance· February 26, 2026

Aeva Reports Fourth Quarter and Full Year 2025 Results

View original at finance.yahoo.com

Aeva Reports Fourth Quarter and Full Year 2025 Results Awarded Major Global Production Contract from Top 10 Passenger OEM Selected by Top 5 Passenger OEM for Global Vehicle Development Program Nvidia Selected Aeva as Reference LiDAR Sensor for DRIVE Hyperion Platform Doubled Revenue in 2025 Driven by Scaling Volume and…

Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

Aeva's momentum expected to continue with additional production program opportunities, scaling manufacturing and delivering another record revenue year
80% confidence
Aeva will deliver C-samples to Daimler Truck in 2026 as exclusive long-range LiDAR and primary detection sensor for series production autonomous trucks
80% confidence
Top 10 European OEM production program has targeted SOP in 2028
80% confidence
2025 was a landmark year for Aeva, marked by accelerating demand for unique perception platform from growing list of customers and strategic partners across broad applications
80% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página

En vivo desde el sustrato

Lo que estamos viendo

AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts

AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.

Nuestra lectura de los datos ›

Señales que seguimos

Satellite-Terrestrial Network Integration Acceleration

Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases

Patrones que observamos ›

Donde las fuentes discrepan

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

Señalamos los conflictos abiertamente ›

Verificado recientemente

✓ Verificado con la fuente original

4,985

hechos rastreados a su fuente — y señalamos los que no se sostienen.

101 entidades seguidas4,985 hechos verificados con la fuente5,317 documentos fuente archivados

Consulta estos datos → isubstrate.com